# Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis

Study · id `cardio:ct-nct04349683` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04349683](<https://clinicaltrials.gov/study/NCT04349683>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04349683

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 332 participants.

## Technical summary

Registry record NCT04349683. Randomized; double masking; primary purpose treatment. Start 2020-04-30 (anticipated); primary completion 2021-08-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 332 participants (planned count; ClinicalTrials.gov record NCT04349683, source copy `cardio:ctgov-nct04349683-2020-04-20`, retrieved 2026-10-26)
- Planned start: 2020-04-30 (anticipated) (ClinicalTrials.gov record NCT04349683, source copy `cardio:ctgov-nct04349683-2020-04-20`, retrieved 2026-10-26)
- Primary completion: 2021-08-30 (anticipated) (ClinicalTrials.gov record NCT04349683, source copy `cardio:ctgov-nct04349683-2020-04-20`, retrieved 2026-10-26)
- Completion: 2021-10-30 (anticipated) (ClinicalTrials.gov record NCT04349683, source copy `cardio:ctgov-nct04349683-2020-04-20`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04349683-2020-04-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis
- Condition: Chronic Kidney Disease Stage 3B
- Condition: Chronic Kidney Disease stage4
- Condition: Glomerulonephritis
- Intervention (Drug): Jinshuibao
- Intervention (Drug): Placebo
- Lead sponsor: Jemincare
- Lead sponsor class: INDUSTRY
- Collaborator: Shanghai 6th People's Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as a collaborator: Shanghai 6th People's Hospital (`cardio:org-shanghai-6th-people-s-hospital`)

## Provenance

Content hash: 692cb205975575be20d946b5ec618b679645928639b6b64202dfb42d55aabe5e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
